Board summary
Key figures
43,566
Registered population
67.6% aged 18–64
15.4%
Aged 65+
ICB 18.8% · England 17.9%
16.8%
Ethnic minority (non-White)
9.0% Asian · England 9.6%
1.6%
In IMD quintile 1
ICB 0.8% · England 21.0%
~689
Core20 residents (est.)
Resident basis; registered basis ~743 · see page 3
5,431
Hypertension register
+3.30% in 3 yrs · England +5.60%
406
SMI register
37.9% of Guildford's
571
COPD register
Reviews -8.33% in 3 yrs
Forecast to 2030
6,476
Hypertension patients, 2030
+1,045 on today
62.4%
QRISK ≥20% on statins, 2030
+2.90pp over 3 yrs
4.2%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Asthma annual reviews fall behind national growth.
Over 2023 to 2025, asthma reviews fell 4.7% (England +4.4%) to 63.1%, leaving 951 of 2,577 patients unreviewed, which may reflect recall gaps.
High-risk lipid therapy coverage trails England.
Lipid-lowering therapy for QRISK ≥ 20% is 56.1%, below Guildford (57.3%), the ICB (59.4%) and England by 7.4 pp (63.6%), warranting recall audit.
Hypertension treatment to target improved over three years.
Over 2023 to 2025, hypertension control rose +11.6% (+7.2 pp versus England +2.5 pp), reaching 69.2% against 70.3% across England.
Population, age and ethnicity
A working-age population predominates alongside 8.8% projected list growth to 2030
Central and North Guildford PCN registers 43,566 patients across Woodbridge Hill Surgery (17,144), Fairlands Medical Practice (13,966), and Dapdune House Surgery (12,456). Working-age adults aged 18–64 account for 67.6% (Guildford 63.8%, ICB 60.8%, England 62.7%). Patients aged 65+ represent 15.4% (6,725; Guildford 17.5%, England 17.9%). An unverified model projects 8.8% list growth to 2030 (England 2.3%). In Census resident data, not registered patients, White ethnicity is 83.2% (England 81.1%) and Asian is 9.0% (Guildford 6.7%, England 9.6%), reaching 11.2% at Woodbridge Hill Surgery and 10.2% at Dapdune House Surgery.
Age profile
65+: ICB 18.8%, England 17.9%
Ethnicity
Older people · falls rows are Guildford local-authority (LA) data, not PCN
| Measure | Local | South East | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Guildford LA) | 2,163 | 2,018 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 82.6% | 82.2% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 53.4% | 57.8% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Guildford LA) | 1,054 | 981 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Guildford LA) | 9.4 | 14.0 | 14.8 | 2022‑24 |
Deprivation and Core20
Core20 deprivation affects 1.6% of patients, concentrating mostly at Woodbridge Hill Surgery
Central and North Guildford PCN records an average IMD decile of 7.6 (Guildford 7.9, NHS Surrey Heartlands Integrated Care Board 7.9, England 5.5). Core20 prevalence is 1.6% (Guildford 1.0%, ICB 0.8%, England 21.0%). Resident Core20 estimates total 689 persons across deciles 1 and 2, which differ from 743 across practice registers. Both Core20 concentration and volume peak at Woodbridge Hill Surgery (2.3%, 389 estimated patients), ahead of Dapdune House Surgery (1.6%, 206) and Fairlands Medical Practice (1.1%, 148).
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
406
SMI register
0.94% recorded prevalence
185
Learning disability register
0.43% recorded prevalence
18
Care homes, 581 beds
In the PCN catchment
8.0%
Provide unpaid care
Guildford, Census 2021
Recorded learning disability prevalence is 0.4% (185 patients; Guildford 0.4%, ICB 0.5%, England 0.6%), and severe mental illness is 0.9% (406 patients; Guildford 0.8%, ICB 0.8%, England 1.0%). Catchment care homes total 18 with 581 beds, without confirmed registered residency.
Severe mental illness: physical health checks
SMI physical checks trail England for blood pressure (81.5% vs 83.4%) and BMI (79.4% vs 82.1%), with Fairlands Medical Practice recording 76.9% for blood pressure. These shortfalls could reflect recall capacity gaps to verify locally.
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
5,431
Hypertension register
+3.30%
Register growth, 3 yrs
Guildford +5.63% · England +5.60%
+8.59pp
BP control, under 80
≤140/90 · +5.18pp aged 80+
+1,045
More patients by 2030
Forecast 6,476 (13.35%)
Hypertension case-finding and control
Hypertension prevalence is 12.5% (5,431 patients), matching Guildford (12.5%) but below NHS Surrey Heartlands ICB (14.3%) and England (15.2%). Although treatment to target rose +11.6% (+7.2 pp versus England +2.5 pp) over 2023 to 2025, current control is 69.2% (England 70.3%). Blood pressure control among patients aged 80 and over trails at 77.9% against England (81.2%), reaching 74.4% at Dapdune House Surgery and 80.6% at Woodbridge Hill Surgery. Unadjusted register scenarios (+13 to +1,204 patients) are likely overstated given the PCN's younger population (15.4% aged 65+). Older hypertensive patients remain below national control benchmarks, so prioritising structured clinical reviews at practices with lower control rates could narrow the management gap.
Lipids and statins
For patients with QRISK ≥ 20%, lipid-lowering therapy coverage is 56.1%, below Guildford (57.3%), NHS Surrey Heartlands ICB (59.4%), and England (63.6%). CKD lipid coverage also trails England (63.6% versus 70.3%). Fewer at-risk patients receive lipid-lowering therapy than England implies, so prioritising recall audits for high-risk cohorts is an immediate operational step.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 42,989 | £2.20 | £2.24 | £1.86 | £94,576 |
| Cardiovascular (all), 2025 | 63,950 | £5.16 | £4.74 | £3.33 | £329,982 |
In 2026, the PCN prescribed 42,989 items of lipid-regulating drugs at £2.20 per item (Guildford £2.15, NHS Surrey Heartlands ICB £2.24, England £1.86), spending £14,616 more than at England's unit cost. Higher unit costs than England suggest an opportunity to review local formulary choices and item mix across practices.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
−4.73%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
−0.70%
Asthma prevalence, PCN 3-yr % change
Annual respiratory reviews have declined: COPD reviews fell 8.3% to 76.7% over 2023 to 2025 (England +2.8% to 76.4%), and asthma reviews fell 4.7% to 63.1% (England +4.4% to 65.7%). Across 2,577 asthma patients, about 950 lack a recorded review, reaching 55.9% at Woodbridge Hill Surgery. Meanwhile, asthma management prescribing reaches 1,225 items per 1,000 aged 5-19, above Guildford (838). Falling reviews alongside higher local prescribing may reflect recall pressures to verify locally.
Cancer register and children's immunisation
Cancer register prevalence is 3.5% (1,537 patients), below England (3.8%). In Q1 2025/26, 4-in-1 booster coverage at age 5 reached 89.1% (denominator 92), below the 95.0% target by 5.9 pp. Age-5 MMR drops 5.5 pp between dose 1 (95.7%) and dose 2 (90.2%), widening to an 11.4 pp drop at Woodbridge Hill Surgery (100.0% to 88.6%), which could reflect recall gaps to verify locally.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
61.4%
Surrey Heartlands ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~650
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Surrey Heartlands ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Prostate | 65.7% | 53.2% | 18% | 1,044 |
| Breast | 88.2% | 85.4% | 27% | 798 |
| Bowel | 48.1% | 47.0% | 18% | 626 |
| Lung | 33.2% | 33.8% | 17% | 497 |
| Skin cancer | 89.8% | 87.8% | 19% | 384 |
At ICB level in 2022 (not published at PCN level), NHS Surrey Heartlands ICB diagnosed 61.4% of staged cancers at stage 1 or 2 (England 55.3%), 13.6 pp below the 75.0% national ambition, requiring about 650 extra early-stage cases annually across 4,810 staged cases (67.7% known stage). PCN cancer prevalence is 3.5% across 1,537 patients (England 3.8%). Cervical screening coverage at ages 25-49 is 61.0%, below England (66.8%) and the ICB (69.3%) after a -2.9% three-year change over 2023 to 2025 (England -1.0%), reaching 56.5% at Woodbridge Hill Surgery and 57.0% at Dapdune House Surgery. Prioritising screening uptake at lower-coverage practices could support earlier presentation across local pathways.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
At acute trust level (not PCN performance), July 2026 provisional cancer 62-day waits at Royal Surrey NHS Foundation Trust reached 84.5% (standard 85.0%), above NHS Surrey and Sussex Integrated Care Board (71.5%), England (71.2%), and Ashford and St Peter's Hospitals NHS Foundation Trust (76.4%), with Frimley Health NHS Foundation Trust at 81.8%. Faster diagnosis reached 82.6% (standard 75.0%; ICB 79.3%, England 79.3%) and 31-day treatment 96.4% (standard 96.0%). Diagnostic 6-week waits were 8.8% (England 23.1%), with colonoscopy at 0.0% but audiology assessments at 49.7% (Ashford and St Peter's 0.6%, England 41.5%).
| Pathways within standard (%) | Royal Surrey | Frimley Health | Ashford and St Peter's | Surrey and Sussex ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 82.62 | 87.95 | 85.53 | 79.29 | 79.32 |
| 31-day treatment (96%) | 96.43 | 92.89 | 94.21 | 90.45 | 92.50 |
| 62-day referral to treatment (85%) | 84.48 | 81.84 | 76.38 | 71.51 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Royal Surrey | Frimley Health | Ashford and St Peter's | England |
|---|---|---|---|---|
| MRI | 0.00 | 12.85 | 0.09 | 21.40 |
| CT | 0.15 | 0.63 | 9.27 | 9.92 |
| Echocardiography | 1.55 | 3.35 | 0.97 | 28.48 |
| Colonoscopy | 0.00 | 22.84 | 49.61 | 30.83 |
| Gastroscopy | 0.00 | 7.43 | 56.74 | 29.02 |
| All 15 DM01 tests | 8.82 | 7.49 | 23.12 | 23.14 |
| Community services activity | Surrey residents | Surrey and Sussex ICB |
|---|---|---|
| Care contacts | 109,530 | 309,615 |
| Referrals | 28,700 | 66,930 |
| Patients with a contact | 33,510 | 85,660 |
Community services (residents of Surrey), Jun 2026 (provisional). In June 2026 (provisional), Surrey residents recorded 109,530 community care contacts and 66,060 care activities, with 69.6% of contacts among adults aged 65+. Across NHS Surrey and Sussex Integrated Care Board, recorded activity totalled 309,615 care contacts and 316,320 care activities. These experimental figures reflect submitting providers across the wider system rather than exclusive PCN caseloads.
Practice variation and patient experience
Vaccination achievement varies by 44.1 pp across practices despite uniform telephone access
In 2025/26, clinical-domain QOF achievement reached 100.0% at Dapdune House Surgery against England's 97.1%, 100.0% at Woodbridge Hill Surgery, and 97.2% at Fairlands Medical Practice. In contrast, vaccination and immunisation achievement spanned a 44.1 pp range, from 42.7% at Fairlands Medical Practice to 86.8% at Dapdune House Surgery (England 55.2%).
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Fairlands Medical | 114 | 1.1 | 67.4% | 76.6% | 87.0% |
| Woodbridge Hill | 120 | 2.3 | 66.3% | 54.6% | 77.2% |
| Dapdune House | 82 | 1.6 | 66.1% | 77.1% | 75.4% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
17 of 25 three-year trajectories trail England, led by falling respiratory reviews
Across 25 compared three-year trajectories over 2023 to 2025, 17 PCN measures trail England. The widest lags are in chronic disease reviews: COPD reviews fell 8.3% (England +2.8%), asthma reviews fell 4.7% (England +4.4%), heart failure reviews rose +2.0% (England +8.7%), and smoking cessation offers fell 2.7 pp (England +0.1 pp). Conversely, relative gains outpaced England in hypertension blood pressure control under 80 (+14.7% versus England +3.2%), hypertension treated to target (+11.6% versus England +3.6%), dementia prevalence (+15.9% versus England +6.0%), and learning disability prevalence (+11.9% versus England +5.4%).
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
COPD reviews
Asthma reviews
Heart failure reviews
Stroke register
Smoking support (SMI)
BP control, under 80
Hypertension treated to target
BP control, 80+
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Guildford | Asset | PCN | Guildford |
|---|---|---|---|---|---|
| Care homes (catchment) | 18 (581 beds) | n/a | Schools (catchment) | 74 | n/a |
| Children's centres | 4 | 6 | Places of worship | 37 | 78 |
| Libraries | n/a | 3 | Homelessness support (VCS) | 0 | 1 |
| Day centres (VCS) | n/a | 2 | Carers support groups (VCS) | n/a | 1 |
| Primary schools (LA maintained) | 5 | 14 | Primary academies | 11 | 19 |
| Special schools | 1 | no data |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Structured asthma review recall
Asthma reviews are 63.1% (Guildford 67.8%, ICB 65.6%, England 65.7%; 55.9% at Woodbridge Hill Surgery) after falling 4.7% over 2023 to 2025 (England +4.4%), leaving 951 of 2,577 patients unreviewed. For discussion: run single-template asthma recall alongside inhaler prescribing checks, offering flexible review slots at lower-coverage practices. Moderate effort to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 2
Combined SMI physical health checks
Across 406 SMI register patients, annual blood pressure checks are 81.5% (Guildford 84.9%, ICB 83.5%, England 83.4%; Fairlands Medical Practice 76.9%) and BMI checks are 79.4% (England 82.1%). For discussion: introduce combined physical check appointments, template audits for partial checks, and named outreach leads for non-attenders. Moderate effort to run.
Evidence base: the SMI register is the cohort for the annual physical health check; the alcohol record is the delivery measure for alcohol screening and brief intervention.
Policy anchor: Mental Health Investment Standard; NHS alcohol care teams and the From Harm to Hope strategy.
Option 3
High-risk CVD lipid therapy recall
Patients with QRISK ≥ 20% on lipid-lowering therapy reach 56.1%, below Guildford (57.3%), ICB (59.4%), and England (63.6%) after +5.4% change over 2023 to 2025; CKD lipid therapy is 63.6% (England 70.3%). Moderate effort to run.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Culturally tailored access review (p2) | Asian / Asian British | Neighbourhood health framework · Core20PLUS5 approach | PCN |
| Targeted Core20 outreach (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| Systematic SMI physical checks (p4) | SMI register with a BP check in the last 12 months | MHIS · From Harm to Hope | PCN |
| Hypertension control review (p5) | Last BP reading of patients (80+ yrs with hypertension) in the last 12 months is <= 150/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Pre-school booster recall (p6) | 4-in-1 pre-school booster (DTaP/IPV) coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Targeted cervical screening outreach (p7) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | PCN |
| Appointment booking and queue review (p9) | GPPS last request led to a booked appointment | 10YHP, hospital to community | Practice |
| Option 1 · Structured asthma review recall (p12) | Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) | Core20PLUS5 respiratory | PCN & Practice |
| Option 2 · Combined SMI physical health checks (p12) | Severe mental illness register · SMI register with a BP check in the last 12 months · SMI register with a BMI recorded in the last 12 months | MHIS · From Harm to Hope | PCN & Practice |
| Option 3 · High-risk CVD lipid therapy recall (p12) | Patients with QRISK ≥ 20% treated with lipid lowering therapy · CKD patients treated with lipid lowering therapy | — | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | ICB | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
